EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Arch Therapeutics's enterprise value is $11.87 Mil.
Arch Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.12 Mil. Therefore, Arch Therapeutics's EV-to-Revenue for today is 102.33.
The historical rank and industry rank for Arch Therapeutics's EV-to-Revenue or its related term are showing as below:
ARTH'
s EV-to-Revenue Range Over the Past 10 Years
Min: 97.34 Med: 777.71 Max: 2730.84
Current: 102.33
During the past 13 years, the highest EV-to-Revenue of Arch Therapeutics was 2730.84. The lowest was 97.34. And the median was 777.71.
ARTH's EV-to-Revenue is ranked worse than 84.22% of 1039
companies
in the Biotechnology industry
Industry Median: 8.37
vs ARTH: 102.33
The historical data trend for Arch Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Arch Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Arch Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arch Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arch Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Arch Therapeutics's EV-to-Revenue falls into.
Arch Therapeutics's current Enterprise Value is $11.87 Mil.
Arch Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arch Therapeutics's share price for today is $1.04.
Arch Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arch Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Arch Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Arch Therapeutics (Arch Therapeutics) Business Description
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARTH has been successfully added to your 